

Developed under the direction and sponsorship of Shire Pharmaceuticals. Contains promotional material.

FOR YOUR PATIENTS

Taking Care of the Skin They're In: Expert Advice About Daytrana and Children's Skin
PDF Download (1.5 MB)

Dr. Sharon Jacob

Director, Contact Dermatitis Clinic of the University of Miami-Miller School of Medicine and Assistant Professor, Clinical Dermatology, Department of Dermatology and Cutaneous Surgery; President, Florida Contact Dermatitis Society and a consultant for Shire US Inc.

Full Prescribing Information

Important Safety Information

DAYTRANA.com

ADHDSupport.com

Shire: Your ADHD Support Company™

TREAT ME LIKE ME…

With DAYTRANA™: The Methylphenidate Patch

The next evolution in the delivery of methylphenidate (MPH)¹
DOT Matrix™ patch technology provides continuous delivery¹ for smooth levels of medication²
Efficacy from the first time point measured (2 hours) through 12 hours, with the recommended 9-hour wear time¹
Individualized duration of effect to meet the changing daily needs of patients and parents¹
Daytrana is indicated as an integral part of a comprehensive ADHD treatment program that may include other measures (psychological, educational, and social). The efficacy of Daytrana was established in clinical trials in children aged 6 to 12 years¹

NEXT ARTICLE…

How the Patch Works

Important Safety Information

Daytrana should not be used in patients with allergy to methylphenidate or patch components; marked anxiety, tension and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. Patients should avoid applying external heat to the Daytrana patch. Erythema has been commonly reported. Contact sensitization may occur.

Daytrana should be given cautiously to patients with a history of drug dependence and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder.

Common adverse events reported by patients who received Daytrana in clinical trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, and anorexia, consistent with adverse events commonly associated with the use of methylphenidate.

^†McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9:476-485.

Link to Full Prescribing Information | Important Safety Information | DAYTRANA.com | ADHDSupport.com